ICU Profile
SeaStar Medical Holding Corporation is a medical device company specializing in innovative solutions for treating hyperinflammation and cytokine storms in critically ill patients. The company's primary focus is on developing and commercializing extracorporeal therapies designed to address systemic inflammation. These therapies target the effector cells responsible for driving inflammation, which can cause direct tissue damage and trigger a cascade of pro-inflammatory cytokines that lead to severe immune system imbalances.
SeaStar Medical's product pipeline encompasses a range of therapeutic areas. This includes treatments for acute kidney injury in both pediatric and adult patients undergoing continuous renal replacement therapy (CRRT), as well as cardiorenal syndrome associated with congestive heart failure, whether or not the patient has a left ventricular assist device (LVAD). The company also targets myocardial stunning in end-stage renal disease and hepatorenal syndrome, expanding its focus to address complex conditions that result from systemic inflammation.
The company is at the forefront of advancing novel medical technologies aimed at mitigating the effects of severe inflammatory responses. By developing therapies that directly intervene in the inflammatory process, SeaStar Medical seeks to improve outcomes for critically ill patients and address unmet medical needs in the field of extracorporeal medicine.
Founded and headquartered in Denver, Colorado, SeaStar Medical Holding Corporation is dedicated to advancing its innovative therapeutic solutions and contributing to the evolving landscape of critical care medicine. Its strategic focus on hyperinflammation and cytokine storm positions it as a key player in addressing complex medical challenges associated with severe inflammatory conditions.
|
